Quantitative Drug Safety and Benefit Risk Evaluation Quantitative Drug Safety and Benefit Risk Evaluation
Chapman & Hall/CRC Biostatistics Series

Quantitative Drug Safety and Benefit Risk Evaluation

Practical and Cross-Disciplinary Approaches

William Wang and Others
    • $64.99
    • $64.99

Publisher Description

Quantitative Methodologies and Process for Safety Monitoring and Ongoing Benefit Risk Evaluation provides a comprehensive coverage on safety monitoring methodologies, covering both global trends and regional initiatives. Pharmacovigilance has traditionally focused on the handling of individual adverse event reports however recently there had been a shift towards aggregate analysis to better understand the scope of product risks.

Written to be accessible not only to statisticians but also to safety scientists with a quantitative interest, this book aims to bridge the gap in knowledge between medical and statistical fields creating a truly multi-disciplinary approach that is very much needed for 21st century safety evaluation.

GENRE
Science & Nature
RELEASED
2021
December 30
LANGUAGE
EN
English
LENGTH
402
Pages
PUBLISHER
CRC Press
SELLER
Taylor & Francis Group
SIZE
11.5
MB

More Books Like This

The Duty for Sponor Oversight in Clinical Trials The Duty for Sponor Oversight in Clinical Trials
2022
Proposals to Enhance the Quality of Observational Cohort Studies (Review) Proposals to Enhance the Quality of Observational Cohort Studies (Review)
2003
A Review of the Draft Report of the NCI-CDC Working Group to Revise the 1985 Radioepidemiological Tables A Review of the Draft Report of the NCI-CDC Working Group to Revise the 1985 Radioepidemiological Tables
2000
Analytical Performance Characteristics should be Judged Against Objective Quality Specifications (Editorial) Analytical Performance Characteristics should be Judged Against Objective Quality Specifications (Editorial)
1999
Tipping Points Tipping Points
2015
Panel Discussion: How to Monitor and Minimize Variation and Mistakes (Clinical Chemistry Forum) (Discussion) Panel Discussion: How to Monitor and Minimize Variation and Mistakes (Clinical Chemistry Forum) (Discussion)
1997

More Books by William Wang, Melvin Munsaka, James Buchanan & Judy Li

Other Books in This Series

Medical Risk Prediction Models Medical Risk Prediction Models
2021
Biomarker Analysis in Clinical Trials with R Biomarker Analysis in Clinical Trials with R
2020
Biosimilar Clinical Development: Scientific Considerations and New Methodologies Biosimilar Clinical Development: Scientific Considerations and New Methodologies
2016
Real-World Evidence in Drug Development and Evaluation Real-World Evidence in Drug Development and Evaluation
2021
Statistical Design, Monitoring, and Analysis of Clinical Trials Statistical Design, Monitoring, and Analysis of Clinical Trials
2021
Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials Hybrid Frequentist/Bayesian Power and Bayesian Power in Planning Clinical Trials
2022